SLC5A2 and metabolic syndrome: We have recently shown that SGLT2 inhibitors improve disrupted circadian rhythms of BP in metabolic syndrome rats [SHR/NDmcr-cp(+/+) rats; SHRcp] (37) and salt-treated obese Otsuka Long Evans Tokushima Fatty (OLETF) rats (44), both of which show non-dipper type of hypertension.